The Aspace Catalunya Foundation and the Sant Joan de Déu Hospital lead a key study for the diagnosis of MECP2 duplication syndrome
To the Aspace Catalonia Foundation, we work with a clear objective: that research generates real changes in people's lives. For this reason, together with the Hospital Sant Joan de Déu, we have led a study published in the scientific journal Diagnostics, Which represents a step forward in the diagnosis and assessment of MECP2 duplication syndrome, a rare genetic disease that affects neurological development.
This work, the result of a strategic collaboration, has combined clinical methodology and advanced technology to create new diagnostic and monitoring toolsThe objective is clear: to facilitate diagnosis, improve the quality of life of affected people and offer families faster and more accurate answers.
MECP2 duplication syndrome: a little-known disease with great impact
La MECP2 duplication syndrome It is a rare genetic condition that affects the neurological development and communication of people who have it.It is due to a duplication of the MECP2 gene., essential for the functioning of the nervous system, and manifests itself in various ways, with difficulties in speech, movement and coordination.
Despite being a minority disease, its The impact on the daily lives of people and their families is significant., and early diagnosis can be key to improving care and support. For this reason, research is essential to advance knowledge of this syndrome, facilitate its detection and offer new tools that improve the quality of life of those affected.
Science and technology at the service of people
Aware of the need for more efficient detection and care, this study has allowed:
- Developing the MECPDup Scale, an innovative clinical scale that allows measuring the severity of the syndrome and optimizing its monitoring. This tool has demonstrated a strong correlation with other medical metrics, facilitating more personalized care.
- Apply artificial intelligence in diagnosis. The use of the Face2Gene platform has allowed training a system capable of identifying facial features characteristic of MECP2 duplication syndrome, helping to speed up diagnosis and reduce uncertainty for many families.
- Relate clinical and genetic data to better understand how the size of the MECP2 gene duplication influences the severity of symptoms, opening new avenues of research for the future development of more precise therapies.
A key study for the future of treatments
One of the major advances of this study has been the development of the MECPDup Scale, an innovative tool that It not only allows the severity of MECP2 duplication syndrome to be assessed, but it is also essential for describing the natural history of the disease and monitoring the effect of new therapies.
This aspect is particularly relevant, since currently The first clinical trial in Spain for this disease is about to begin., opening a new stage in the search for treatments. In addition, this study underlines the importance of interdisciplinary collaboration across medical geneticists, neurologists, psychologists, genetic biologists and other specialists, who work together to advance knowledge and intervention for this condition.
This approach multidisciplinary is essential to ensure a better understanding of the syndrome and offer effective tools to improve the quality of life of affected people and their families.
The value of research: improving diagnosis, intervention and quality of life
This study It would not have been possible without the leadership and direct involvement of the Aspace Catalunya Foundation and the Sant Joan de Déu Hospital. Our commitment to research places us at the center of advances in the field of neurodevelopmental diseases and allows us to continue developing innovative solutions to improve the diagnosis and care of people with disabilities.
Link to the post: Vega-Hanna, L., Casas-Alba, D., Balsells, S., Bolasell, M., Rubio, P., García-García, A., … & Martinez-Monseny, AF (2024). MECP2 Duplication Syndrome: AI-Based Diagnosis, Severity Scale Development and Correlation with Clinical and Molecular Variables. Diagnostics, 15(1), 10. https://www.mdpi.com/2075-4418/15/1/10
